The award of the highest award in the field of oncology in Shanghai highlights the precision of oncology diagnosis and treatment and the fine management of the whole process.

The 5th Shanghai Cancer Science and Technology Award was awarded on the 30th.
12 projects show the general direction and new height of cancer diagnosis and treatment research in Shanghai in recent years.
Shanghai Anti-Cancer Association told reporters on the 30th, these award-winning projects emphasize the precision of cancer diagnosis and treatment and the whole process of fine management, in multidisciplinary cooperation to jointly solve the diagnosis and treatment problems, and academic results into clinical energy, improve patient prognosis and survival.
It is learned that the Shanghai Cancer Science and Technology Award is the highest award in the field of cancer in Shanghai, the winning project team for different areas of cancer difficulties, from basic research, strategy establishment to the promotion of results, showing the major medical institutions in Shanghai research team in promoting the accuracy of cancer diagnosis and treatment and management steps.
The Shanghai Anti-Cancer Association will actively promote the innovation in the diagnosis and treatment of cancer in Shanghai to the whole country.
it is understood that professor Zhai Zhimin of Fudan University's affiliated oncology hospital in Shanghai and Professor Chen Wei of Shanghai Lung Hospital won the first prize of the Cancer Science and Technology Award.
The research project, chaired by Professor Zhai Zhimin, focused on the three-negative breast cancer with the highest degree of malignancy and the worst prognostic prognosticity, and mapped the multi-groups of Chinese groups of three-negative breast cancer, established the preferred chemotherapy program for three-negative breast cancer, and revealed a new strategy for reversing chemotherapy resistance.
's team also accurately predicted the risk of recurrence and metastasis of triple negative breast cancer, revealing new therapeutic targets.
lung cancer is the most morbid and fatal cancer.
screening, surgical decision-making, identification of high-risk groups with recurrence and auxiliary treatment are all difficulties in individual diagnosis and treatment.
this, Professor Chen's team continued to conduct research, from preoperative, in-art, post-operative multi-node series of research.
team to revolutionize lung cancer screening strategies and preoperative imaging diagnostic systems.
researchers independently developed two lung cancer early screening liquid biopsy products, the establishment of early lung cancer artificial intelligence imaging diagnostic system, so that the detection rate of early lung cancer increased by 15.8%.
they also perfected the specifications for minimally invased surgery for early lung cancer.
Professor Chen Zhen, chairman of the Shanghai Anti-Cancer Association and vice president of Fudan University's affiliated Oncology Hospital, said in an interview that as a reservoir for The China Anti-Cancer Science and Technology Award and even higher, the Shanghai Anti-Cancer Science and Technology Award encourages more cancer-fighting front-line cancer researchers to constantly reform and innovate, optimize diagnosis and treatment, and bring high-quality projects to the Chinese and even the world stage.
Chen Jing Tang Jiazhen Source: China News Network Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medical and are not authorized to be reproduced by any media, website or individual, and must be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.